Table 2 Sensitivity of Multi-cancer Signal Detection by Clinical Stage
Company | Test (cost/ proposed cost) | Molecular origin | Specificity (%) | Sensitivity | |||
|---|---|---|---|---|---|---|---|
Stage I (%) | Stage II (%) | Stage III (%) | Stage IV (%) | ||||
Dxcover [46]a (UK) | Dxcover cancer liquid biopsy ($300) (sensitivity tuned) | Spectroscopic pan-omics | 58 | 99 | 97 | 99 | 98 |
Dxcover [46]a (UK) | Dxcover cancer liquid biopsy ($300) (specificity tuned) | Spectroscopic pan-omics | 99 | 64 | 51 | 62 | 57 |
Grail [11]b (USA) | Galleri ($949) [134] | Methylomics | 99.5 | 16.8 | 40.4 | 77.0 | 90.1 |
Thrive [52]a (USA) | CancerSEEK ($-) | cfDNA and biomarkers |  > 99 | 43 | 73 | 78 | N/A |